Loading oncology approvals…
Loading oncology approvals…
Regulatory
Every record is one authority's decision for one application or DIN, shown with its jurisdiction, date, indication text as published and status. A molecule approved in one jurisdiction for one indication is not 'approved' in general.
RegulatoryDevelopment pipeline →Methodology
Coverage
Counts of records, not of drugs approved: one application can carry several dated records (original approval, efficacy supplements, one row per DIN in Canada).
Approval records
4,342
Distinct drugs
373
Records naming a cancer
982
Dated in the last 12 months
179
| Authority | Jurisdiction | Records | Drugs | In force | Withdrawn / cancelled | Last 12 months | Latest dated record |
|---|---|---|---|---|---|---|---|
| FDA | US | 2,343 | 304 | 2,343 | 0 | 115 | Sep 18, 2026 |
| Health Canada | CA | 1,538 | 273 | 979 | 559 | 44 | Sep 22, 2026 |
| EMA | EU | 461 | 246 | 386 | 75 | 20 | Sep 18, 2026 |
Data updated 2 days agoSource updated unknown3 authority · jurisdiction pairs ingested
Feed
Latest approval date first; records without a date are listed last. Filters combine.
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Jan 6, 2006 | Anagrelide | Health Canada CA | cancer not stated in this record | Marketed in Canada as PMS-ANAGRELIDE (DIN 02274949) under ATC L01XX35 ANAGRELIDE. Indications are not published in the Drug Product… | DIN02274949 | approvedsource: Marketed | health-canada-dpd |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Dec 15, 2005 | Triptorelin | Health Canada CA | cancer not stated in this record | Marketed in Canada as TRELSTAR (DIN 02243856) under ATC L02AE04 TRIPTORELIN. Indications are not published in the Drug Product Database —… | DIN02243856 |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Nov 2, 2005 | Bevacizumab | Health Canada CA | cancer not stated in this record | Marketed in Canada as AVASTIN (DIN 02270994) under ATC L01FG01 BEVACIZUMAB. Indications are not published in the Drug Product Database —… | DIN02270994 |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Aug 15, 2005 | Leuprolide | Health Canada CA | cancer not stated in this record | Marketed in Canada as ELIGARD (DIN 02268892) under ATC L02AE02 LEUPRORELIN. Indications are not published in the Drug Product Database —… | DIN02268892 |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Jul 19, 2005 | Erlotinib | Health Canada CA | cancer not stated in this record | Marketed in Canada as TARCEVA (DIN 02269023) under ATC L01EB02 ERLOTINIB. Indications are not published in the Drug Product Database — see… | DIN02269023 |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Apr 11, 2005 | Anagrelide | Health Canada CA | cancer not stated in this record | Marketed in Canada as MYLAN-ANAGRELIDE (DIN 02253054) under ATC L01XX35 ANAGRELIDE. Indications are not published in the Drug Product… | DIN02253054 |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Feb 7, 2005 | Paclitaxel | Health Canada CA | cancer not stated in this record | Marketed in Canada as APO-PACLITAXEL INJECTABLE (DIN 02248844) under ATC L01CD01 PACLITAXEL. Indications are not published in the Drug… | DIN02248844 |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Dec 22, 2004 | Vinorelbine | Health Canada CA | cancer not stated in this record | Marketed in Canada as VINORELBINE TARTRATE FOR INJECTION (DIN 02257777) under ATC L01CA04 VINORELBINE. Indications are not published in the… | DIN |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Nov 5, 2004 | Anagrelide | Health Canada CA | cancer not stated in this record | Marketed in Canada as SANDOZ ANAGRELIDE (DIN 02260107) under ATC L01XX35 ANAGRELIDE. Indications are not published in the Drug Product… | DIN02260107 |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Oct 25, 2004 | Imatinib | Health Canada CA | cancer not stated in this record | Marketed in Canada as GLEEVEC (DIN 02253283) under ATC L01EA01 IMATINIB. Indications are not published in the Drug Product Database — see… | DIN02253283 |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Sep 17, 2004 | Peginterferon Alfa-2b | Health Canada CA | cancer not stated in this record | Marketed in Canada as PEGETRON (DIN 02254646) under ATC L03AB60 PEGINTERFERON ALFA-2B, COMBINATIONS. Indications are not published in the… | DIN |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Aug 3, 2004 | Pemetrexed | Health Canada CA | cancer not stated in this record | Marketed in Canada as ALIMTA (DIN 02253437) under ATC L01BA04 PEMETREXED. Indications are not published in the Drug Product Database — see… | DIN02253437 |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Jun 14, 2004 | Fulvestrant | Health Canada CA | cancer not stated in this record | Marketed in Canada as FASLODEX (DIN 02248624) under ATC L02BA03 FULVESTRANT. Indications are not published in the Drug Product Database —… | DIN02248624 |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| May 26, 2004 | Peginterferon Alfa-2a | Health Canada CA | cancer not stated in this record | Marketed in Canada as PEGASYS RBV (DIN 02253429) under ATC L03AB61 PEGINTERFERON ALFA-2A, COMBINATIONS. Indications are not published in… | DIN |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Apr 29, 2004 | Leuprolide | Health Canada CA | cancer not stated in this record | Marketed in Canada as ELIGARD (DIN 02248999) under ATC L02AE02 LEUPRORELIN. Indications are not published in the Drug Product Database —… | DIN02248999 |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Mar 12, 2004 | Pegfilgrastim | Health Canada CA | cancer not stated in this record | Marketed in Canada as NEULASTA (DIN 02249790) under ATC L03AA13 PEGFILGRASTIM. Indications are not published in the Drug Product Database —… | DIN02249790 |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Dec 17, 2003 | Gefitinib | Health Canada CA | cancer not stated in this record | Marketed in Canada as IRESSA (DIN 02248676) under ATC L01EB01 GEFITINIB. Indications are not published in the Drug Product Database — see… | DIN02248676 |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Nov 18, 2003 | Cyclophosphamide | Health Canada CA | cancer not stated in this record | Marketed in Canada as PROCYTOX (DIN 02241799) under ATC L01AA01 CYCLOPHOSPHAMIDE. Indications are not published in the Drug Product… | DIN02241799 |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Oct 22, 2003 | Hydroxyurea | Health Canada CA | cancer not stated in this record | Marketed in Canada as APO-HYDROXYUREA (DIN 02247937) under ATC L01XX05 HYDROXYCARBAMIDE. Indications are not published in the Drug Product… | DIN02247937 |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Aug 14, 2003 | Peginterferon Alfa-2a | Health Canada CA | cancer not stated in this record | Marketed in Canada as PEGASYS (DIN 02248078) under ATC L03AB11 PEGINTERFERON ALFA-2A. Indications are not published in the Drug Product… | DIN |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Apr 15, 2003 | Ifosfamide | Health Canada CA | cancer not stated in this record | Marketed in Canada as IFOSFAMIDE FOR INJECTION (DIN 02246565) under ATC L01AA06 IFOSFAMIDE. Indications are not published in the Drug… | DIN02246565 |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Sep 24, 2002 | Fludarabine | Health Canada CA | cancer not stated in this record | Marketed in Canada as FLUDARA (DIN 02246226) under ATC L01BB05 FLUDARABINE. Indications are not published in the Drug Product Database —… | DIN02246226 |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Aug 13, 2002 | Peginterferon Alfa-2b | Health Canada CA | cancer not stated in this record | Marketed in Canada as PEGETRON (DIN 02246030) under ATC L03AB60 PEGINTERFERON ALFA-2B, COMBINATIONS. Indications are not published in the… | DIN |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Jul 2, 2002 | Carmustine | Health Canada CA | cancer not stated in this record | Marketed in Canada as GLIADEL WAFER (DIN 02238985) under ATC L01AD01 CARMUSTINE. Indications are not published in the Drug Product Database… | DIN02238985 |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| May 1, 2002 | Glatiramer | Health Canada CA | cancer not stated in this record | Marketed in Canada as COPAXONE (DIN 02245619) under ATC L03AX13 GLATIRAMER ACETATE. Indications are not published in the Drug Product… | DIN02245619 |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Dec 21, 2001 | Doxorubicin | Health Canada CA | cancer not stated in this record | Marketed in Canada as MYOCET (DIN 02245015) under ATC L01DB01 DOXORUBICIN. Indications are not published in the Drug Product Database — see… | DIN02245015 |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Nov 14, 2001 | Methotrexate | Health Canada CA | cancer not stated in this record | Marketed in Canada as RATIO-METHOTREXATE SODIUM (DIN 02244798) under ATC L01BA01 METHOTREXATE. Indications are not published in the Drug… | DIN |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Oct 31, 2001 | Paclitaxel | Health Canada CA | cancer not stated in this record | Marketed in Canada as PACLITAXEL FOR INJECTION (DIN 02244372) under ATC L01CD01 PACLITAXEL. Indications are not published in the Drug… | DIN02244372 |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Sep 26, 2001 | Imatinib | Health Canada CA | cancer not stated in this record | Marketed in Canada as GLEEVEC (DIN 02244725) under ATC L01EA01 IMATINIB. Indications are not published in the Drug Product Database — see… | DIN02244725 |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Apr 23, 2001 | Valrubicin | Health Canada CA | cancer not stated in this record | Marketed in Canada as VALTAXIN (DIN 02242466) under ATC L01DB09 VALRUBICIN. Indications are not published in the Drug Product Database —… | DIN02242466 |
A record is one authority's decision for one application/DIN; the same molecule appears once per jurisdiction and indication. Health Canada DPD does not publish indications — its records state the brand, DIN and ATC class only, and a cancelled or dormant DIN is the status of one product, not of the molecule. FDA cancer mappings come from label text and are flagged probabilistic on the drug page.
| approvedsource: Marketed |
| health-canada-dpd |
| Dec 15, 2005 | Triptorelin | Health Canada CA | cancer not stated in this record | Marketed in Canada as TRELSTAR (DIN 02240000) under ATC L02AE04 TRIPTORELIN. Indications are not published in the Drug Product Database —… | DIN02240000 | approvedsource: Marketed | health-canada-dpd |
| Dec 2, 2005 | Interferon Beta-1a | Health Canada CA | cancer not stated in this record | Marketed in Canada as AVONEX (DIN 02269201) under ATC L03AB07 INTERFERON BETA-1A. Indications are not published in the Drug Product… | DIN02269201 | approvedsource: Marketed | health-canada-dpd |
| approvedsource: Marketed |
| health-canada-dpd |
| approvedsource: Marketed |
| health-canada-dpd |
| withdrawnsource: Cancelled Post Marketsince Oct 1, 2024 |
| health-canada-dpd |
| Jul 19, 2005 | Erlotinib | Health Canada CA | cancer not stated in this record | Marketed in Canada as TARCEVA (DIN 02269015) under ATC L01EB02 ERLOTINIB. Indications are not published in the Drug Product Database — see… | DIN02269015 | withdrawnsource: Cancelled Post Marketsince Oct 1, 2024 | health-canada-dpd |
| withdrawnsource: Cancelled Post Marketsince Jun 28, 2016 |
| health-canada-dpd |
| Apr 5, 2005 | Imatinib | Health Canada CA | cancer not stated in this record | Marketed in Canada as GLEEVEC (DIN 02253275) under ATC L01EA01 IMATINIB. Indications are not published in the Drug Product Database — see… | DIN02253275 | approvedsource: Marketed | health-canada-dpd |
| withdrawnsource: Dormantsince Aug 4, 2017 |
| health-canada-dpd |
| Feb 1, 2005 | Bortezomib | Health Canada CA | cancer not stated in this record | Marketed in Canada as VELCADE (DIN 02262452) under ATC L01XG01 BORTEZOMIB. Indications are not published in the Drug Product Database — see… | DIN02262452 | approvedsource: Marketed | health-canada-dpd |
| withdrawnsource: Cancelled Post Marketsince Apr 6, 2021 |
| health-canada-dpd |
| withdrawnsource: Cancelled Post Marketsince Feb 4, 2020 |
| health-canada-dpd |
| approvedsource: Marketed |
| health-canada-dpd |
| withdrawnsource: Cancelled Post Marketsince Oct 5, 2017 |
| health-canada-dpd |
| Sep 17, 2004 | Peginterferon Alfa-2b | Health Canada CA | cancer not stated in this record | Marketed in Canada as PEGETRON (DIN 02254638) under ATC L03AB60 PEGINTERFERON ALFA-2B, COMBINATIONS. Indications are not published in the… | DIN02254638 | withdrawnsource: Cancelled Post Marketsince Oct 5, 2017 | health-canada-dpd |
| Sep 17, 2004 | Peginterferon Alfa-2b | Health Canada CA | cancer not stated in this record | Marketed in Canada as PEGETRON (DIN 02254603) under ATC L03AB60 PEGINTERFERON ALFA-2B, COMBINATIONS. Indications are not published in the… | DIN02254603 | withdrawnsource: Cancelled Post Marketsince Oct 5, 2017 | health-canada-dpd |
| Sep 17, 2004 | Peginterferon Alfa-2b | Health Canada CA | cancer not stated in this record | Marketed in Canada as PEGETRON (DIN 02254581) under ATC L03AB60 PEGINTERFERON ALFA-2B, COMBINATIONS. Indications are not published in the… | DIN02254581 | withdrawnsource: Cancelled Post Marketsince Oct 5, 2017 | health-canada-dpd |
| withdrawnsource: Cancelled Post Marketsince Sep 17, 2021 |
| health-canada-dpd |
| approvedsource: Marketed |
| health-canada-dpd |
| Jun 3, 2004 | Aminolevulinic Acid | Health Canada CA | cancer not stated in this record | Marketed in Canada as LEVULAN KERASTICK (DIN 02243933) under ATC L01XD04 AMINOLEVULINIC ACID. Indications are not published in the Drug… | DIN02243933 | approvedsource: Marketed | health-canada-dpd |
| withdrawnsource: Cancelled Post Marketsince Jul 10, 2018 |
| health-canada-dpd |
| May 26, 2004 | Peginterferon Alfa-2a | Health Canada CA | cancer not stated in this record | Marketed in Canada as PEGASYS RBV (DIN 02253410) under ATC L03AB61 PEGINTERFERON ALFA-2A, COMBINATIONS. Indications are not published in… | DIN02253410 | withdrawnsource: Cancelled Post Marketsince Jul 10, 2018 | health-canada-dpd |
| approvedsource: Marketed |
| health-canada-dpd |
| Apr 12, 2004 | Methotrexate | Health Canada CA | cancer not stated in this record | Marketed in Canada as METHOTREXATE TABLETS, USP (DIN 02182750) under ATC L01BA01 METHOTREXATE. Indications are not published in the Drug… | DIN02182750 | approvedsource: Marketed | health-canada-dpd |
| approvedsource: Marketed |
| health-canada-dpd |
| approvedsource: Marketed |
| health-canada-dpd |
| Dec 1, 2003 | Leuprolide | Health Canada CA | cancer not stated in this record | Marketed in Canada as ELIGARD (DIN 02248240) under ATC L02AE02 LEUPRORELIN. Indications are not published in the Drug Product Database —… | DIN02248240 | approvedsource: Marketed | health-canada-dpd |
| Dec 1, 2003 | Leuprolide | Health Canada CA | cancer not stated in this record | Marketed in Canada as ELIGARD (DIN 02248239) under ATC L02AE02 LEUPRORELIN. Indications are not published in the Drug Product Database —… | DIN02248239 | approvedsource: Marketed | health-canada-dpd |
| approvedsource: Marketed |
| health-canada-dpd |
| Nov 3, 2003 | Cyclophosphamide | Health Canada CA | cancer not stated in this record | Marketed in Canada as PROCYTOX (DIN 02241800) under ATC L01AA01 CYCLOPHOSPHAMIDE. Indications are not published in the Drug Product… | DIN02241800 | approvedsource: Marketed | health-canada-dpd |
| approvedsource: Marketed |
| health-canada-dpd |
| withdrawnsource: Cancelled Post Marketsince Jul 27, 2017 |
| health-canada-dpd |
| Aug 14, 2003 | Peginterferon Alfa-2a | Health Canada CA | cancer not stated in this record | Marketed in Canada as PEGASYS (DIN 02248077) under ATC L03AB11 PEGINTERFERON ALFA-2A. Indications are not published in the Drug Product… | DIN02248077 | approvedsource: Marketed | health-canada-dpd |
| withdrawnsource: Cancelled Post Marketsince Aug 29, 2024 |
| health-canada-dpd |
| approvedsource: Marketed |
| health-canada-dpd |
| withdrawnsource: Cancelled Post Marketsince Apr 4, 2017 |
| health-canada-dpd |
| Aug 13, 2002 | Peginterferon Alfa-2b | Health Canada CA | cancer not stated in this record | Marketed in Canada as PEGETRON (DIN 02246029) under ATC L03AB60 PEGINTERFERON ALFA-2B, COMBINATIONS. Indications are not published in the… | DIN02246029 | withdrawnsource: Cancelled Post Marketsince Jan 23, 2013 | health-canada-dpd |
| Aug 13, 2002 | Peginterferon Alfa-2b | Health Canada CA | cancer not stated in this record | Marketed in Canada as PEGETRON (DIN 02246028) under ATC L03AB60 PEGINTERFERON ALFA-2B, COMBINATIONS. Indications are not published in the… | DIN02246028 | withdrawnsource: Cancelled Post Marketsince Jan 23, 2013 | health-canada-dpd |
| Aug 13, 2002 | Peginterferon Alfa-2b | Health Canada CA | cancer not stated in this record | Marketed in Canada as PEGETRON (DIN 02246027) under ATC L03AB60 PEGINTERFERON ALFA-2B, COMBINATIONS. Indications are not published in the… | DIN02246027 | withdrawnsource: Cancelled Post Marketsince Jan 23, 2013 | health-canada-dpd |
| Aug 13, 2002 | Peginterferon Alfa-2b | Health Canada CA | cancer not stated in this record | Marketed in Canada as PEGETRON (DIN 02246026) under ATC L03AB60 PEGINTERFERON ALFA-2B, COMBINATIONS. Indications are not published in the… | DIN02246026 | withdrawnsource: Cancelled Post Marketsince Apr 4, 2017 | health-canada-dpd |
| withdrawnsource: Cancelled Post Marketsince Mar 2, 2015 |
| health-canada-dpd |
| approvedsource: Marketed |
| health-canada-dpd |
| withdrawnsource: Dormantsince Sep 7, 2018 |
| health-canada-dpd |
| Dec 3, 2001 | Mitoxantrone | Health Canada CA | cancer not stated in this record | Marketed in Canada as MITOXANTRONE INJECTION USP (DIN 02244614) under ATC L01DB07 MITOXANTRONE. Indications are not published in the Drug… | DIN02244614 | withdrawnsource: Cancelled Post Marketsince Mar 26, 2019 | health-canada-dpd |
| withdrawnsource: Cancelled Post Marketsince May 7, 2018 |
| health-canada-dpd |
| approvedsource: Marketed |
| health-canada-dpd |
| withdrawnsource: Cancelled Post Marketsince Sep 24, 2008 |
| health-canada-dpd |
| withdrawnsource: Cancelled Post Marketsince Aug 1, 2017 |
| health-canada-dpd |